1g versus 2g Daily Intravenous Ceftriaxone in the Treatment of Community Onset Pneumonia –a propensity score analysis of data from a Japanese multicenter registry

Authors:

Abstract
Objectives: Community-onset pneumonia (COP) is a supplant concept of community acquired pneumonia, which includes the previous classification of healthcare-associated pneumonia. Although ceftriaxone (CRO) is one of the treatment choices for COP, it is unclear whether 1 or 2 g CRO daily has better efficacy. We compared the effectiveness of 1 g with 2 g of CRO for COP treatment. We hypothesized that 1 g CRO would show non-inferiority over 2 g CRO. Methods: This study was an analysis of prospectively registered data from four Japanese hospitals for patients with COP (the Adult Pneumonia Study Group-Japan: APSG-J). Subjects who were initially treated solely with 1 or 2 g of CRO were enrolled. The propensity score was estimated from the 33 pre-treatment variables, including age, sex, weight, pre-existing comorbidities, prescribed drugs prior to admission, risk factors for aspiration pneumonia, vital signs, laboratory data, and findings from chest xrays. The primary endpoint was the cure rate, for which a non-inferiority analysis was performed with a margin of 0.05. In addition, we performed three sensitivity analyses; using data limited to the group in which CRO solely was used until the completion of treatment, using data limited for inpatient cases, and including a generalised linear mixed-effect logistic regression analysis to assess the primary outcome after adjusting for random hospital effects. Results: Of the 3,817 adult subjects with pneumonia who were registered in the APSG-J study, 290 and 216 were initially treated solely with 1 or 2 g of CRO, respectively. Propensity score matching was used to extract 175 subjects in each group. The cure rate was 94.6% and 93.1% in the 1 and 2 g CRO groups, respectively (risk difference, 1.5%; 95% confidence interval, −3.1 to 6.0; p = 0.009 for non-inferiority). The results of the sensitivity analyses were consistent with the primary result. Conclusions: The propensity score-matched analysis of multicenter cohort data from Japan revealed that the cure rate for COP patients treated with 1 g CRO was non-inferior to that of patients treated with CRO.
All Related Versions